HeartBeam Receives Analyst Upgrade Following FDA Clearance Milestone

HeartBeam (NASDAQ: BEAT) was featured in a recent article highlighting Joseph Gunnar & Co.'s upgrade of the company from Hold to Buy and raising of its 12-month price target to $4 from $1. The February 2026 report cited regulatory progress and the company's transition toward commercialization as key factors. The report stated, "We upgrade HeartBeam to a BUY and High-Risk rating with a raised price target of $4 (from $1), reflecting progress in cardiac risk detection." This upgrade represents a significant turning point for HeartBeam following FDA clearance of its 12-lead ECG synthesis software in December 2025 for arrhythmia assessment.

The FDA clearance resolved an earlier regulatory setback and allowed HeartBeam to transition to commercial-stage status, marking a pivotal moment in the company's development. This regulatory milestone enables the medical technology company to advance its platform technology designed to transform cardiac care by providing powerful cardiac insights wherever the patient is located. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions, which physicians can use to identify cardiac health trends and acute conditions outside of traditional medical facilities.

The technology's potential to redefine cardiac health management has attracted attention from analysts who recognize the commercial implications of FDA clearance. The upgrade reflects confidence in HeartBeam's ability to capitalize on its 13 U.S. and 4 international-issued patents related to technology enablement. For more information about the company, visit https://www.HeartBeam.com. The full article discussing the analyst upgrade can be accessed at https://ibn.fm/NrrYt, while the latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.

Investors should note that certain statements in the original article are forward-looking as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from expressed expectations. Full terms of use and disclaimers applicable to all content provided by IBN are available at http://IBN.fm/Disclaimer. The original release was published on www.newmediawire.com, where readers can find complete information about the regulatory progress and commercial implications discussed in the analyst report.